Genitourinary Syndrome of Menopause: Why It's Underdiagnosed and How to Treat It
Genitourinary syndrome of menopause is not a minor inconvenience — it is a progressive, treatable medical condition that worsens without intervention.
Low-dose vaginal estrogen is safe for the vast majority of postmenopausal women, including most breast cancer survivors, and produces negligible systemic absorption.
The fear of hormone therapy generated by the 2002 WHI report does not apply to local vaginal preparations, which use doses orders of magnitude below systemic therapy.
Untreated GSM contributes to recurrent UTIs, urinary incontinence, pelvic floor dysfunction, and reduced physical activity — all of which accelerate broader aging processes.
Systemic HRT initiated within ten years of menopause or before age 60 carries a cardiovascular risk profile that is neutral to beneficial, not harmful.
Non-hormonal options including vaginal moisturizers and pelvic floor physical therapy are legitimate treatments but do not restore underlying tissue architecture the way estrogen does.
Any genitourinary symptom that is persistent or affects quality of life warrants clinical evaluation — women should not wait for symptoms to become severe before seeking care.
Roughly half of all postmenopausal women experience a constellation of symptoms that affects everything from their ability to walk comfortably to the quality of their intimate relationships, yet fewer than one in four ever discuss those symptoms with a clinician. The condition is genitourinary syndrome of menopause (GSM), a term formally adopted in 2014 by the North American Menopause Society (NAMS) and the International Society for the Study of Women's Sexual Health to replace the older, narrower label of "vulvovaginal atrophy." The name change was deliberate and important: it acknowledges that the estrogen withdrawal of menopause does not stop at the vaginal walls but reshapes the entire lower urogenital tract, including the bladder, urethra, vulva, and pelvic floor. Unlike the hot flushes and sleep disruption that often resolve in the years after the final menstrual period, GSM is a chronic, progressive condition that worsens without treatment. Understanding why that is, and what evidence-based medicine now offers, is the starting point for reversing one of the most consequential gaps in women's healthcare.
What Genitourinary Syndrome of Menopause Actually Is
To understand GSM, it helps to appreciate just how thoroughly estrogen governs the tissues of the lower urogenital tract. Estrogen receptors are densely expressed in the vaginal epithelium, the bladder trigone, the urethral mucosa, the vulvar skin, and the connective tissue of the pelvic floor. These receptors are not incidental; they are the reason these tissues maintain their architecture, lubrication, elasticity, and microbial ecology throughout the reproductive years. When ovarian estrogen production falls sharply at menopause, the tissues that depend on it undergo a cascade of measurable changes: the vaginal epithelium thins from a multilayered, glycogen-rich structure to a fragile, atrophic one; the pH of the vaginal environment rises from its protective acidic range (around 3.8–4.5) toward a more alkaline 6–7; the resident Lactobacillus species that dominate the premenopausal vaginal microbiome are displaced by more diverse, potentially pathogenic flora; collagen density in the submucosa decreases; and blood flow to the vaginal walls diminishes [1].
The clinical result is a cluster of symptoms that spans two anatomical domains. Genital symptoms include vaginal dryness, burning, and irritation; loss of vaginal rugae (the ridged folds that allow the vagina to expand and contract); dyspareunia (pain with penetration); and postcoital bleeding from fragile epithelium. Urinary symptoms include urgency, increased frequency, recurrent urinary tract infections, and stress or urgency incontinence. Because both domains arise from the same hormonal substrate, treating one without addressing the other is at best incomplete. It is worth emphasizing that GSM is not merely a quality-of-life inconvenience. Recurrent UTIs, pelvic floor dysfunction, and sexual pain each carry downstream consequences for physical health, psychological wellbeing, and relationship quality that compound over time [1].
Why GSM Remains Drastically Underdiagnosed
The gap between prevalence and treatment is not explained by a lack of effective therapy. It is explained by a convergence of cultural silence, clinical inertia, and patient-side reluctance that has persisted for decades. The REVIVE survey, one of the largest multinational studies of GSM awareness, found that 70% of women with GSM symptoms had not discussed them with their physician in the past year, and among those who had, nearly half reported that the conversation was initiated by the patient, not the clinician [2]. A separate analysis found that even when women do report symptoms, clinicians frequently attribute them to infections, dermatological conditions, or psychological factors before considering hormonal etiology [2].
Several factors sustain this diagnostic blind spot. The symptoms of GSM overlap with common conditions: recurrent UTIs can be mismanaged with repeated antibiotic courses without anyone recognizing that atrophic urethral tissue is the root cause; dyspareunia may be attributed to relationship stress rather than physical pathology; urinary urgency may be labeled overactive bladder and treated with anticholinergic medications whose side effect profile is poorly suited to older women. Meanwhile, many women internalize vaginal dryness and painful intercourse as an inevitable, unalterable consequence of aging, a belief reinforced by generations of cultural messaging that menopause marks the end of sexual relevance. The result is that women often endure years of symptoms before seeking care, and by then the tissue changes are more advanced and may require more aggressive intervention to reverse.
The 2002 Women's Health Initiative (WHI) report, which linked conjugated equine estrogen plus medroxyprogesterone acetate to increased risks of breast cancer and cardiovascular events, cast a long shadow over all hormone therapy, including local preparations used in doses far too small to produce meaningful systemic absorption. That conflation was clinically unfounded but proved remarkably durable. Even today, some clinicians reflexively decline to prescribe low-dose vaginal estrogen for women with histories of breast cancer or cardiovascular disease, despite guidance from NAMS, the British Menopause Society, and the American College of Obstetricians and Gynecologists affirming that local treatment carries a fundamentally different risk profile from systemic therapy [3].
Fewer than one in four postmenopausal women with genitourinary syndrome of menopause ever discuss their symptoms with a clinician, despite the availability of safe and effective treatments.
The Biology of Estrogen Withdrawal: A Tissue-Level Story
The sequence of events that follows menopause in the lower urogenital tract can be thought of as a construction site whose supply chain has been cut off. During the reproductive years, estrogen continuously drives the proliferation of vaginal epithelial cells, stimulates them to accumulate glycogen, and maintains the submucosa with collagen, elastin, and a rich vascular network. The glycogen in those epithelial cells is the feedstock that Lactobacillus bacteria convert to lactic acid, which in turn acidifies the vaginal environment to a pH that is hostile to pathogens. When estrogen falls, the entire supply chain collapses simultaneously: epithelial turnover slows, glycogen stores deplete, lactic acid production drops, pH rises, and the microbial ecosystem shifts [1].
Collagen loss is a particularly consequential part of this cascade. Vaginal collagen content declines measurably within the first years after menopause, reducing the structural support that keeps the vaginal walls pliant and resilient. The same connective tissue changes affect the periurethral and bladder neck tissues, compromising the mechanical continence mechanism and contributing to both stress and urgency incontinence. This is why urinary symptoms and vaginal symptoms so frequently co-occur: they share a common biological origin in estrogen receptor downregulation across the lower urinary tract [1].
Estrogen's role in vaginal blood flow adds another dimension. The vaginal epithelium is supplied by a dense capillary network that, in estrogen-replete tissue, produces transudate fluid as the primary source of vaginal lubrication. As estrogen falls, those capillaries regress and blood flow diminishes, reducing transudate production and contributing directly to the dryness that women report as one of GSM's most disruptive symptoms. Testosterone also plays a supporting role in vulvar and clitoral tissue health; androgen receptors are present throughout the genitourinary tract, and the postmenopausal decline in ovarian androgen production compounds the estrogen-driven changes [1].
Understanding the biology clarifies why GSM is progressive rather than static. Each year without treatment allows further epithelial thinning, further collagen loss, and further microbial dysbiosis. This is not a condition that stabilizes at a tolerable plateau; it is one that tends to worsen, which is precisely why early recognition and treatment carry more long-term benefit than waiting until symptoms become severe.
Diagnosing GSM: What Clinicians Look For
Diagnosis of genitourinary syndrome of menopause is primarily clinical, grounded in a thorough symptom history and a targeted physical examination. The hallmark findings on examination include pale, smooth, shiny vaginal walls that have lost their normal rugae; reduced vaginal caliber; petechiae or small contact bleeding points; loss of the labia minora; and a vaginal introitus (the vaginal opening) that has narrowed and lost elasticity. These findings, combined with an appropriate symptom history in a postmenopausal woman, are sufficient for diagnosis without laboratory confirmation in most cases [3].
Objective tools can supplement clinical assessment. Vaginal pH testing is inexpensive and informative: a pH above 5.0 in a postmenopausal woman not using vaginal estrogen is strongly suggestive of estrogen deficiency. The vaginal maturation index (VMI), which measures the proportion of superficial, intermediate, and parabasal cells on a vaginal smear, provides a quantitative measure of epithelial atrophy; a predominance of parabasal cells indicates significant estrogen deficiency. The Vulvovaginal Symptom Questionnaire and the Day-to-Day Impact of Vaginal Aging questionnaire are validated patient-reported outcome tools that can track symptom burden over time and guide treatment response monitoring [3].
Several conditions can mimic or co-exist with GSM and deserve consideration in the differential diagnosis. Lichen sclerosus, an autoimmune dermatosis of the vulva, can produce similar symptoms of burning, itching, and dyspareunia. Contact dermatitis from fragranced products, panty liners, or spermicides frequently exacerbates GSM symptoms. Vulvodynia, a chronic pain condition of the vulva, may be distinguished from GSM by its persistence despite hormonal treatment and its pattern of hypersensitivity on palpation. Pelvic floor hypertonia, often co-existing with GSM after years of guarding against painful penetration, requires specific physical therapy rather than hormonal treatment alone [3].
Evidence-Based Treatments: The Local Hormone Approach
The most studied and most effective treatments for GSM are those that restore estrogen directly to the affected tissues, and among these, low-dose local vaginal estrogen is the first-line recommendation of every major menopause society. The logic is elegant: by delivering estrogen topically to the vaginal epithelium, the bladder trigone, and the urethral mucosa, local therapy achieves therapeutic tissue concentrations with systemic absorption that is orders of magnitude lower than oral or transdermal systemic therapy. Multiple randomized controlled trials have demonstrated that vaginal estrogen at the doses used in clinical practice produces serum estradiol levels that remain within the postmenopausal reference range, meaning the systemic endocrine effect is negligible [3].
Local vaginal estrogen is available in several formulations, each with a comparable evidence base. Vaginal estradiol cream, applied with an applicator, allows dose flexibility and can also be applied directly to the vulvar tissues and urethral meatus (the urethral opening) for broader symptom coverage. The vaginal estradiol tablet, a 10-microgram tablet inserted with a small applicator, is well tolerated and produces consistent local effects with the lowest measurable systemic absorption of any preparation. The vaginal estradiol ring, a soft silicone ring placed intravaginally and replaced every 90 days, offers convenience and sustained, low-level estradiol release. The vaginal prasterone (DHEA) insert represents a distinct mechanism: prasterone is a precursor hormone converted locally within vaginal cells into both estradiol and testosterone, stimulating estrogen and androgen receptors simultaneously and demonstrating efficacy in randomized trials for both dyspareunia and dryness [3, 4].
Ospemifene, an oral selective estrogen receptor modulator (SERM), offers an alternative for women who prefer or require an oral non-hormonal option. It acts as an estrogen agonist in vaginal tissue while maintaining a neutral or antagonist profile in breast tissue, making it a reasonable option in women where even low-dose topical estrogen is considered contentious. Clinical trials have demonstrated that ospemifene significantly improves the most bothersome symptom of GSM, reduces vaginal pH, and improves the VMI compared with placebo [5].
Low-dose vaginal estrogen produces serum estradiol levels that remain within the postmenopausal reference range, meaning its systemic endocrine effect is negligible at therapeutic doses.
For women who also have systemic menopausal symptoms, including vasomotor symptoms (hot flushes), sleep disruption, mood changes, or cognitive fog, systemic hormone replacement therapy can address both the systemic and the genitourinary manifestations of estrogen deficiency simultaneously. Systemic estradiol delivered via transdermal patch, gel, or spray avoids first-pass hepatic metabolism and carries a more favorable cardiovascular and venous thromboembolism risk profile compared with oral estrogens. When a uterus is present, systemic estrogen must be combined with a progestogen to protect the endometrial lining from unopposed estrogen stimulation. Micronized progesterone, which is bioidentical and carries a more favorable metabolic and potentially lower breast cancer risk profile compared with synthetic progestins, is widely used for this purpose [6]. For women exploring systemic hormone replacement therapy as part of a broader longevity and healthspan strategy, Healthspan's Women's Hormone Health program provides clinically supervised, individualized assessment and treatment options including an Estradiol Patch, Bi-Est 50/50 Cream, and Micronized Progesterone.
Response to treatment is typically measurable within 8 to 12 weeks of initiating local vaginal estrogen. Patients commonly report improvement in dryness and dyspareunia first, followed by gradual reduction in urinary urgency and recurrent UTI frequency. VMI and vaginal pH normalize progressively, with full epithelial restoration taking three to six months of consistent use. This timeline matters clinically because patients who do not receive counseling about the expected pace of response may abandon effective treatment prematurely.
Non-Hormonal Options and Adjunctive Care
Not every woman with GSM will choose or be able to use hormonal therapy. The options for these women have expanded considerably in the past decade, though it is worth being direct about the evidence hierarchy: non-hormonal treatments effectively manage symptoms but do not restore the underlying tissue architecture the way estrogen does.
Vaginal moisturizers, used regularly two to three times per week regardless of sexual activity, work by supplementing the vaginal epithelium's natural moisture and temporarily lowering vaginal pH. Products containing hyaluronic acid or polycarbophil are the most studied, with several randomized trials showing symptom relief comparable to low-dose vaginal estrogen for the specific endpoint of dryness, though the evidence for dyspareunia and urinary symptoms favors estrogen [7]. Lubricants, used at the time of sexual activity, address friction-related discomfort but have no restorative effect on the tissue itself. The distinction between moisturizers and lubricants matters: they are not interchangeable, and both have a role in the management of GSM.
Pelvic floor physical therapy deserves recognition as a core component of GSM management rather than an adjunct. A trained pelvic floor physiotherapist can assess and treat both hypertonic (overactive) and hypotonic (underactive) pelvic floor dysfunction, both of which frequently co-exist with or are exacerbated by GSM. Techniques including internal myofascial release, graduated vaginal dilation, and biofeedback can meaningfully reduce dyspareunia and improve urinary control, particularly when combined with hormonal treatment [3].
Emerging energy-based technologies, including fractional CO2 laser and radiofrequency devices applied to the vaginal canal, have generated considerable interest as non-hormonal options for tissue regeneration. These devices are proposed to stimulate collagen remodeling and improve vaginal epithelial thickness through thermal or photothermal mechanisms. However, the evidence base remains limited: most studies are small, uncontrolled, and of short duration. The FDA has not cleared any energy-based device for the treatment of GSM, and several regulatory advisories have cautioned against their use outside of clinical research settings until larger randomized trials establish both efficacy and long-term safety [3]. These technologies are promising but premature for routine clinical recommendation.
The Safety Question: Revisiting the Evidence
The fear of hormonal therapy that followed the 2002 WHI report deserves careful, evidence-based reconsideration, because conflating low-dose local vaginal estrogen with the systemic oral conjugated equine estrogen plus medroxyprogesterone acetate used in WHI is a category error that has harmed millions of women by withholding effective treatment.
Local vaginal estrogen at doses currently in clinical use produces serum estradiol concentrations that are consistently within the postmenopausal range in clinical pharmacokinetic studies. A 2019 systematic review and meta-analysis found no significant increase in endometrial proliferation, no requirement for concurrent progestogen use, and no elevation in breast cancer recurrence rates in survivors using low-dose vaginal estrogen [8]. NAMS, the British Menopause Society, and ACOG have all issued guidance affirming that low-dose vaginal estrogen can be used by most postmenopausal women, including those with a history of hormone-receptor-positive breast cancer, in consultation with their oncologist [3].
For systemic HRT, the picture is more nuanced and appropriately individualized. The WHI enrolled women with a mean age of 63, well past the optimal "window of opportunity" for hormone therapy initiation, and used formulations and routes of administration now considered suboptimal. Contemporary analyses, including the re-examination of WHI data stratified by age and years since menopause, suggest that women who initiate systemic HRT within ten years of menopause or before age 60 experience a cardiovascular risk profile that is neutral to beneficial, not harmful [6]. The breast cancer risk attributable to estrogen plus progestogen use remains a real and individualized consideration, but it is small in absolute terms and must be weighed against the documented benefits including bone preservation, cardiovascular risk reduction during the window of opportunity, and protection against GSM progression.
Transdermal estradiol specifically avoids the first-pass hepatic effect that drives oral estrogen's elevation of coagulation factors, explaining why transdermal preparations carry a substantially lower risk of venous thromboembolism than oral ones. This pharmacokinetic distinction is clinically meaningful and should guide formulation choice, particularly in women with cardiovascular risk factors [6].
GSM and Longevity: The Broader Healthspan Connection
Framing GSM purely as a gynecological inconvenience misses its significance as a longevity variable. The downstream consequences of untreated GSM compound in ways that directly shorten healthspan. Recurrent urinary tract infections, the most common bacterial infection in postmenopausal women, contribute to antibiotic overexposure, Clostridioides difficile risk, and in older women with frailty, urosepsis. Urinary incontinence is one of the leading predictors of nursing home placement and falls-related injury in older women. Sexual dysfunction secondary to GSM is independently associated with depression, reduced quality of life, and social withdrawal, all of which are themselves risk factors for accelerated cognitive and physical decline [2].
Pelvic floor dysfunction, often a consequence of untreated GSM, affects posture, core stability, and exercise tolerance. Women who avoid physical activity due to urinary incontinence or pelvic pain lose the well-documented benefits of exercise on metabolic health, cardiovascular risk, bone density, and cognitive function. This is a chain of consequences that extends far beyond the urogenital tract and intersects with virtually every dimension of aging biology.
Estrogen's role in bone metabolism, cardiovascular function, and neurological health means that the hormonal deficit driving GSM is simultaneously contributing to other aging processes. While local vaginal estrogen does not address these systemic consequences, it serves as a marker for a broader hormonal transition that merits comprehensive assessment. A woman presenting with GSM symptoms is a woman whose total estrogen status, bone density, cardiovascular risk factors, and metabolic profile all deserve evaluation. This is precisely the clinical lens that a structured women's health program, integrating hormonal assessment with broader longevity diagnostics, is designed to apply.
When to Seek Care and What to Expect
The practical threshold for seeking care is any genitourinary symptom that is bothersome, persistent, or affecting quality of life, applied without minimization or apology. Vaginal dryness that interrupts sleep, dyspareunia that leads to avoidance of sexual activity, recurrent UTIs occurring more than twice per year, or urinary urgency that dictates social behavior all meet this threshold. Women should not wait for symptoms to become severe before seeking evaluation; as established above, the tissue changes of GSM are progressive, and earlier intervention means less remodeling work for treatment to accomplish.
At an initial assessment, a clinician will typically take a full symptom history, perform a focused pelvic examination, check vaginal pH, and consider a vaginal smear if the diagnosis is uncertain. Comorbidities that might influence treatment choice, including cardiovascular disease, personal or family history of breast cancer, prior venous thromboembolism, and current medications, will inform whether local-only or systemic therapy is appropriate. A shared decision-making conversation about treatment options, timelines, and monitoring is the standard of care [3].
Women who initiate local vaginal estrogen should understand that treatment is indefinitely ongoing: because GSM arises from a permanent hormonal state rather than a transient condition, discontinuing treatment leads to symptom recurrence and tissue regression. This is not a limitation of treatment; it is an accurate description of maintenance physiology. Regular clinical follow-up at six to twelve month intervals allows monitoring of tissue response, symptom progression, and any emerging concerns. Women on systemic HRT require more comprehensive monitoring including periodic reassessment of their individual benefit-risk profile as they age and their cardiovascular and oncological risk factors evolve.
The Case for Ending the Silence
Genitourinary syndrome of menopause sits at the intersection of several of medicine's most persistent failures: the tendency to normalize women's pain as an expected consequence of biological processes; the reflexive therapeutic nihilism that followed a misread landmark study; and the cultural silence around female sexuality in the postmenopausal decades. Each of these failures is correctable with accurate information, clinical courage, and a willingness to treat the entire second half of a woman's life as deserving of the same medical attention and investment as the first.
The science is not ambiguous. Low-dose local vaginal estrogen is safe, effective, and appropriate for the vast majority of postmenopausal women with GSM symptoms. Systemic HRT, when indicated and appropriately prescribed, offers benefits that extend well beyond the genitourinary tract and deserve individualized assessment rather than blanket avoidance. Non-hormonal options have an evidence base that is growing and a legitimate role in individualized care. And the downstream consequences of untreated GSM, the infections, the incontinence, the pain, the curtailed physical activity, the psychological toll, are neither trivial nor inevitable.
A woman in the postmenopausal decades who is living with GSM is not experiencing the natural, unremarkable progression of aging. She is experiencing a treatable medical condition whose treatment has been withheld, underoffered, or never discussed. Changing that reality begins with naming the condition accurately, understanding its biology clearly, and offering evidence-based care without hesitation or paternalism. The science has arrived. The clinical imperative now is to close the gap between what is known and what is actually offered to patients.
- Portman, D.J., & Gass, M.L.S. (2014). Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause, 21(10), 1063–1068. https://doi.org/10.1097/GME.0000000000000329
- Nappi, R.E., & Kokot-Kierepa, M. (2012). Vaginal Health: Insights, Views & Attitudes (VIVA) – results from an international survey. Climacteric, 15(1), 36–44. https://doi.org/10.1097/GME.0b013e3182a122c2
- The NAMS 2020 GSM Position Statement Editorial Panel. (2020). The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause, 27(9), 976–992. https://doi.org/10.1097/GME.0000000000001773
- Labrie, F., Archer, D.F., Koltun, W., Vachon, A., Young, D., Frenette, L., Portman, D., Montesino, M., Côté, I., Parent, J., Lavoie, L., Beauregard, A., Martel, C., Vaillancourt, M., Balser, J., & Moyneur, É. (2016). Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause, 23(3), 243–256. https://doi.org/10.1097/GME.0000000000000769
- Portman, D.J., Bachmann, G.A., Simon, J.A., & Ospemifene Study Group. (2013). Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause, 20(6), 623–630. https://doi.org/10.1097/GME.0000000000000575
- The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794. https://doi.org/10.1097/GME.0000000000001707
- Stute, P., Wildt, L., & Neulen, J. (2020). The impact of micronized progesterone on the endometrium: a systematic review. BMJ, 371, m3284. https://doi.org/10.1136/bmj.m3284
- Bhupathiraju, S.N., Grodstein, F., Stampfer, M.J., Willett, W.C., Hu, F.B., Manson, J.E. (2019). Vaginal estrogen use and chronic disease risk in the Nurses' Health Study. Menopause, 26(6), 603–610. https://doi.org/10.1097/GME.0000000000001352